Publicity. The Company, and the Buyer shall have the right to review a reasonable period of time before issuance of any press releases, SEC, OTCQB or FINRA filings, or any other public statements with respect to the transactions contemplated hereby; provided, however, that the Company shall be entitled, without the prior approval of the Buyer, to make any press release or SEC, OTCQB (or other applicable trading market) or FINRA filings with respect to such transactions as is required by applicable law and regulations (although the Buyer shall be consulted by the Company in connection with any such press release prior to its release and shall be provided with a copy thereof and be given an opportunity to comment thereon).

Publicity. I consent to any and all uses and displays by the Company of my name, voice, likeness, image, appearance and biographical information in or in connection with any pictures, photographs, audio and video recordings, digital images, websites, television programs, and other advertising and/or printed and electronic forms and media (“Permitted Use”). I hereby release the Company from any and all claims, actions, damages, costs, and liability of any kind in connection with any Permitted Use.

Publicity. [[Company:Organization]] shall afford [[Investor:Organization]] and its counsel with the opportunity to review and comment upon, shall consult with [[Investor:Organization]] and its counsel on the form and substance of, and shall give due consideration to all such comments from [[Investor:Organization]] or its counsel on, any press release, SEC filing or any other public disclosure by or on behalf of [[Company:Organization]] relating to [[Investor:Organization]], its purchases hereunder or any aspect of the Transaction Documents or the transactions contemplated thereby, not less than 24 hours prior to the issuance, filing or public disclosure thereof. [[Investor:Organization]] must be provided with a final version of any such press release, SEC filing or other public disclosure at least 24 hours prior to any release, filing or use by [[Company:Organization]] thereof. [[Company:Organization]] agrees and acknowledges that its failure to fully comply with this provision constitutes a Material Adverse Effect.

Publicity. Neither Party will use the other Party’s name, logo, trademarks, or service marks in any advertising, publicity releases, or any other materials without that Party’s prior written approval.

Publicity. Neither Party shall have the right to make any public announcements with respect to this Agreement, nor publicly disclose the terms of this Agreement, without the prior written consent of the other Party, except as follows:

No Publicity. A Party may not use the name of the other Party in any publicity or advertising and may not issue a press release or otherwise publicize or disclose any information related to the existence of this Agreement or the terms or conditions herein, except # on the advice of its counsel as required by law (e.g., any Securities and Exchange Commission filings and disclosures) and provided the Party who will be disclosing such information has consulted with the other Party to the extent feasible prior to such disclosure with respect to the substance of the disclosure; and # that any press release with respect to the existence of this Agreement or the terms or conditions herein shall be subject to each party’s prior review and approval; and, such approval shall not be unreasonably withheld. Licensee shall provide Merck with reasonable advance written notice of any press release or other public disclosure of the results of any of its work on Licensed Product under this Agreement.

Each of Buyer and Supplier agree not to disclose the existence or contents of this Agreement to any third party without the prior written consent of the other Party except: # to its advisors, attorneys or auditors who have a need to know such information, # as required by law or court order, # as required in connection with the reorganization of a Party, or its merger into any other corporation, or the sale by a Party of all or substantially all of its properties or assets, # as required by a local, state or federal regulatory authorities for either approval of the BDI-747 Ignition Interlock Device for its intended purposes or as a result of the Buyer being a reporting company under the Securities Exchange Act of 1934, as amended, or # as may be required in connection with the enforcement of this Agreement.

During the course of this Agreement, either party may have or may be provided access to the other’s confidential information and materials. Provided such information or materials are marked in a manner reasonably intended to make the recipient aware, or the recipient is sent written notice within forty-eight (48) hours of disclosure, that the information or materials are “Confidential”, each party agrees to maintain such information in accordance with the terms of this Agreement and the CNDA referenced on the signature page of this Agreement or any applicable separate nondisclosure agreement between Buyer and Supplier. In the absence of a CNDA or other written agreement, at a minimum each party agrees to maintain such information in confidence and

Section # Publicity.

SECTION # Confidentiality; Publicity.